Targeted delivery to bone and mineral deposits using bisphosphonate ligands

Lisa E. Cole, Tracy Vargo-Gogola, Ryan K. Roeder

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The high concentration of mineral present in bone and pathological calcifications is unique compared with all other tissues and thus provides opportunity for targeted delivery of pharmaceutical drugs, including radiosensitizers and imaging probes. Targeted delivery enables accumulation of a high local dose of a therapeutic or imaging contrast agent to diseased bone or pathological calcifications. Bisphosphonates (BPs) are the most widely utilized bone-targeting ligand due to exhibiting high binding affinity to hydroxyapatite mineral. BPs can be conjugated to an agent that would otherwise have little or no affinity for the sites of interest. This article summarizes the current state of knowledge and practice for the use of BPs as ligands for targeted delivery to bone and mineral deposits. The clinical history of BPs is briefly summarized to emphasize the success of these molecules as therapeutics for metabolic bone diseases. Mechanisms of binding and the relative binding affinity of various BPs to bone mineral are introduced, including common methods for measuring binding affinity in vitro and in vivo. Current research is highlighted for the use of BP ligands for targeted delivery of BP conjugates in various applications, including (1) therapeutic drug delivery for metabolic bone diseases, bone cancer, other bone diseases, and engineered drug delivery platforms; (2) imaging probes for scintigraphy, fluorescence, positron emission tomography, magnetic resonance imaging, and computed tomography; and (3) radiotherapy. Last, and perhaps most importantly, key structure-function relationships are considered for the design of drugs with BP ligands, including the tether length between the BP and drug, the size of the drug, the number of BP ligands per drug, cleavable tethers between the BP and drug, and conjugation schemes.

Original languageEnglish (US)
Pages (from-to)12-27
Number of pages16
JournalAdvanced Drug Delivery Reviews
Volume99
DOIs
StatePublished - Apr 1 2016

Fingerprint

Diphosphonates
Minerals
Ligands
Bone and Bones
Pharmaceutical Preparations
Bone Neoplasms
Metabolic Bone Diseases
Bone Diseases
Drug Design
Durapatite
Radionuclide Imaging
Positron-Emission Tomography
Contrast Media
Radiotherapy
Therapeutics
Fluorescence
History
Tomography
Magnetic Resonance Imaging

Keywords

  • Bisphosphonate
  • Bone
  • Calcifications
  • Diagnostic imaging
  • Drug Delivery
  • Hydroxyapatite
  • Radiotherapy
  • Targeted delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Targeted delivery to bone and mineral deposits using bisphosphonate ligands. / Cole, Lisa E.; Vargo-Gogola, Tracy; Roeder, Ryan K.

In: Advanced Drug Delivery Reviews, Vol. 99, 01.04.2016, p. 12-27.

Research output: Contribution to journalArticle

@article{7ac10c00ecf643409c9a4a3bcff06dad,
title = "Targeted delivery to bone and mineral deposits using bisphosphonate ligands",
abstract = "The high concentration of mineral present in bone and pathological calcifications is unique compared with all other tissues and thus provides opportunity for targeted delivery of pharmaceutical drugs, including radiosensitizers and imaging probes. Targeted delivery enables accumulation of a high local dose of a therapeutic or imaging contrast agent to diseased bone or pathological calcifications. Bisphosphonates (BPs) are the most widely utilized bone-targeting ligand due to exhibiting high binding affinity to hydroxyapatite mineral. BPs can be conjugated to an agent that would otherwise have little or no affinity for the sites of interest. This article summarizes the current state of knowledge and practice for the use of BPs as ligands for targeted delivery to bone and mineral deposits. The clinical history of BPs is briefly summarized to emphasize the success of these molecules as therapeutics for metabolic bone diseases. Mechanisms of binding and the relative binding affinity of various BPs to bone mineral are introduced, including common methods for measuring binding affinity in vitro and in vivo. Current research is highlighted for the use of BP ligands for targeted delivery of BP conjugates in various applications, including (1) therapeutic drug delivery for metabolic bone diseases, bone cancer, other bone diseases, and engineered drug delivery platforms; (2) imaging probes for scintigraphy, fluorescence, positron emission tomography, magnetic resonance imaging, and computed tomography; and (3) radiotherapy. Last, and perhaps most importantly, key structure-function relationships are considered for the design of drugs with BP ligands, including the tether length between the BP and drug, the size of the drug, the number of BP ligands per drug, cleavable tethers between the BP and drug, and conjugation schemes.",
keywords = "Bisphosphonate, Bone, Calcifications, Diagnostic imaging, Drug Delivery, Hydroxyapatite, Radiotherapy, Targeted delivery",
author = "Cole, {Lisa E.} and Tracy Vargo-Gogola and Roeder, {Ryan K.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.addr.2015.10.005",
language = "English (US)",
volume = "99",
pages = "12--27",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Targeted delivery to bone and mineral deposits using bisphosphonate ligands

AU - Cole, Lisa E.

AU - Vargo-Gogola, Tracy

AU - Roeder, Ryan K.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The high concentration of mineral present in bone and pathological calcifications is unique compared with all other tissues and thus provides opportunity for targeted delivery of pharmaceutical drugs, including radiosensitizers and imaging probes. Targeted delivery enables accumulation of a high local dose of a therapeutic or imaging contrast agent to diseased bone or pathological calcifications. Bisphosphonates (BPs) are the most widely utilized bone-targeting ligand due to exhibiting high binding affinity to hydroxyapatite mineral. BPs can be conjugated to an agent that would otherwise have little or no affinity for the sites of interest. This article summarizes the current state of knowledge and practice for the use of BPs as ligands for targeted delivery to bone and mineral deposits. The clinical history of BPs is briefly summarized to emphasize the success of these molecules as therapeutics for metabolic bone diseases. Mechanisms of binding and the relative binding affinity of various BPs to bone mineral are introduced, including common methods for measuring binding affinity in vitro and in vivo. Current research is highlighted for the use of BP ligands for targeted delivery of BP conjugates in various applications, including (1) therapeutic drug delivery for metabolic bone diseases, bone cancer, other bone diseases, and engineered drug delivery platforms; (2) imaging probes for scintigraphy, fluorescence, positron emission tomography, magnetic resonance imaging, and computed tomography; and (3) radiotherapy. Last, and perhaps most importantly, key structure-function relationships are considered for the design of drugs with BP ligands, including the tether length between the BP and drug, the size of the drug, the number of BP ligands per drug, cleavable tethers between the BP and drug, and conjugation schemes.

AB - The high concentration of mineral present in bone and pathological calcifications is unique compared with all other tissues and thus provides opportunity for targeted delivery of pharmaceutical drugs, including radiosensitizers and imaging probes. Targeted delivery enables accumulation of a high local dose of a therapeutic or imaging contrast agent to diseased bone or pathological calcifications. Bisphosphonates (BPs) are the most widely utilized bone-targeting ligand due to exhibiting high binding affinity to hydroxyapatite mineral. BPs can be conjugated to an agent that would otherwise have little or no affinity for the sites of interest. This article summarizes the current state of knowledge and practice for the use of BPs as ligands for targeted delivery to bone and mineral deposits. The clinical history of BPs is briefly summarized to emphasize the success of these molecules as therapeutics for metabolic bone diseases. Mechanisms of binding and the relative binding affinity of various BPs to bone mineral are introduced, including common methods for measuring binding affinity in vitro and in vivo. Current research is highlighted for the use of BP ligands for targeted delivery of BP conjugates in various applications, including (1) therapeutic drug delivery for metabolic bone diseases, bone cancer, other bone diseases, and engineered drug delivery platforms; (2) imaging probes for scintigraphy, fluorescence, positron emission tomography, magnetic resonance imaging, and computed tomography; and (3) radiotherapy. Last, and perhaps most importantly, key structure-function relationships are considered for the design of drugs with BP ligands, including the tether length between the BP and drug, the size of the drug, the number of BP ligands per drug, cleavable tethers between the BP and drug, and conjugation schemes.

KW - Bisphosphonate

KW - Bone

KW - Calcifications

KW - Diagnostic imaging

KW - Drug Delivery

KW - Hydroxyapatite

KW - Radiotherapy

KW - Targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=84960377783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960377783&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2015.10.005

DO - 10.1016/j.addr.2015.10.005

M3 - Article

VL - 99

SP - 12

EP - 27

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -